Status:
UNKNOWN
Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany
Lead Sponsor:
Ced Service GmbH
Conditions:
Inflammatory Bowel Diseases
Treatment
Eligibility:
All Genders
18-80 years
Brief Summary
This study on biologics (Vedolizumab/anti-TNF) in the treatment of inflammatory bowel disease (IBD) patients in Germany extends the prospective documentation of efficacy in induction and maintenance t...
Detailed Description
The IBD-patients will be prospectively documented in the BIOibd-Registry. The diagnosis is made in accordance with current DGVS/ECCO UC/CD guidelines. There are the following inclusion and exclusion c...
Eligibility Criteria
Inclusion
- IBD-patients (UC/CD) aged 18-80 years at enrollment
- Written informed consent is given
Exclusion
- Lack of adequate documentation possibilities
- Malignant disease in history
- Planned surgical intervention
Key Trial Info
Start Date :
October 2 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2024
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT03375424
Start Date
October 2 2017
End Date
April 30 2024
Last Update
December 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gastroenterologische Gemeinschaftspraxis Minden
Minden, Lower Saxony, Germany, 32423